Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sacituzumab”

202 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 202 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06055465
What this trial is testing

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Chinese University of Hong Kong 37
Not applicableLooking for participantsNCT06240195
What this trial is testing

Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world Study

Who this might be right for
Breast Cancer
Regina Elena Cancer Institute 60
Large-scale testing (Phase 3)Looking for participantsNCT06824467
What this trial is testing

Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Merck Sharp & Dohme LLC 770
Testing effectiveness (Phase 2)Active Not RecruitingNCT06483334
What this trial is testing

Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Who this might be right for
Metastatic Urothelial CarcinomaLocally Advanced Urothelial Carcinoma
Merck Sharp & Dohme LLC 38
Testing effectiveness (Phase 2)Looking for participantsNCT07623577
What this trial is testing

Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases

Who this might be right for
TNBCBrain Metastasis
Fudan University 24
Testing effectiveness (Phase 2)Looking for participantsNCT06040970
What this trial is testing

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Who this might be right for
Ovarian CancerMalignant Neoplasm of Uterus
Icahn School of Medicine at Mount Sinai 54
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07701681
What this trial is testing

Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
ESCCGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma+2 more
Sun Yat-sen University 75
Testing effectiveness (Phase 2)Looking for participantsNCT06235216
What this trial is testing

Sacituzumab govitEcan in THYroid Cancers

Who this might be right for
Differentiated Thyroid CancerAnaplastic Thyroid Cancer
Grupo Espanol de Tumores Neuroendocrinos 42
Large-scale testing (Phase 3)Active Not RecruitingNCT06305754
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 550
Testing effectiveness (Phase 2)Active Not RecruitingNCT05101096
What this trial is testing

Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Triple-Negative Breast CancerHR+/HER2- Metastatic Breast Cancer+1 more
Gilead Sciences 135
Large-scale testing (Phase 3)Looking for participantsNCT05633654
What this trial is testing

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Who this might be right for
Triple Negative Breast Cancer
Gilead Sciences 1,514
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07139470
What this trial is testing

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 59
Testing effectiveness (Phase 2)Looking for participantsNCT05884320
What this trial is testing

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Who this might be right for
GlandSalivary Gland Cancers
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT06178588
What this trial is testing

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Who this might be right for
Locally Advanced CholangiocarcinomaMetastatic CholangiocarcinomaRecurrent Cholangiocarcinoma+4 more
University of Kansas Medical Center 15
Not applicableLooking for participantsNCT07251868
What this trial is testing

Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study

Who this might be right for
Breast CancerBrain Metastases From Breast CancerTrop2
Peking University Cancer Hospital & Institute 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07815197
What this trial is testing

Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer

Who this might be right for
Penile Squamous Cell CarcinomaMetastatic Penile Squamous Cell Carcinoma
Latin American Cooperative Oncology Group 37
Testing effectiveness (Phase 2)Looking for participantsNCT06161532
What this trial is testing

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Who this might be right for
Small Cell Carcinoma of the BladderSmall Cell Carcinoma of the Urinary TractSquamous Cell Carcinoma of the Bladder+5 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT06329869
What this trial is testing

Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT06133517
What this trial is testing

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Who this might be right for
Urothelial Bladder Carcinoma
Fundación para el Progreso de la Oncología en Cantabria 70
Testing effectiveness (Phase 2)Looking for participantsNCT07088211
What this trial is testing

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

Who this might be right for
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University 39
Next Page
60